🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

29 results for “ruxolitinib” Clear

  1. ANAGRELIDE HYDROCHLORIDE MONOHYDRATE, PEGINTERFERON ALFA-2A, MK-3543, BUSULFAN, MK-3543, RUXOLITINIB, MK-3543, MK-3543, RUXOLITINIB, PEGINTERFERON ALFA-2A

    Merck Sharp and Dohme

    Essential Thrombocythemia patients who have an inadequate response to or are intolerant of hydroxyurea

    phase 3 small molecule active

    1 trial

  2. DANAZOL , BUSULFAN , -, POMALIDOMIDE , FEDRATINIB, RUXOLITINIB, PEGFILGRASTIM , HYDROXYCARBAMIDE , PEGINTERFERON ALFA-2A , -

    Celgene Europe Limited

    Primary myelofibrosis, post-polycythemia vera myelofibrosis , or post-essential thrombocythemia myelofibrosis

    phase 3 small molecule active

    1 trial

  3. MaaT013

    Pharma Mar S.A.

    Treatment of acute graft-versus host disease (aGvHD) to the gastrointestinal (GI) tract of patients who are resistant or intolerant to ruxolitinib.

    phase 3 small molecule active

    1 trial

  4. Ruxolitinib (INCB018424) cream, Ruxolitinib (INCB018424) cream, Vehicle (placebo) cream

    Incyte Biosciences Distribution B.V.

    Vitiligo

    phase 3 small molecule active

    1 trial

  5. Ruxolitinib (INCB018424) cream, Vehicle cream (same formulation of cream as the test product but without active substance and the phosphoric acid)

    Incyte Biosciences Distribution B.V.

    Hidradenitis Suppurativa

    phase 3 small molecule active

    1 trial

  6. Vehicle cream (same formulation of cream as the test product but without active substance and the phosphoric acid), Ruxolitinib (INCB018424) cream

    Incyte Biosciences Distribution B.V.

    Hidradenitis Suppurativa

    phase 3 small molecule active

    1 trial

  7. Vehicle cream (same formulation of cream as the test product but without active substance), Ruxolitinib (INCB018424) cream

    Incyte Biosciences Distribution B.V.

    Prurigo Nodularis

    phase 3 small molecule active

    1 trial

  8. Vehicle cream: same formulation of cream as the test product but without active substance and phosphoric acid, Ruxolitinib (INCB018424) cream

    Incyte Biosciences Distribution B.V.

    Atopic Dermatitis

    phase 3 small molecule active

    1 trial

  9. Vehicle cream: same formulation of cream as the test product but without active substance., Ruxolitinib (INCB018424) cream

    Incyte Biosciences Distribution B.V.

    Atopic Dermatitis

    phase 3 small molecule active

    1 trial

  10. A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

    Incyte Biosciences Distribution B.V.

    Anaemia associated with myelofibrosis

    phase 2 other active

    1 trial

  11. Allogeneic Adipose Tissue Derived Mesenchymal Stromal Cells (MSC) ectopically expressing CXCR4 and IL10

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Patients who have developed acute GVHD refractory to corticosteroids and ruxolitinib or that are not eligible to receive ruxolitinib

    phase 2 small molecule active

    1 trial

  12. Azacitidine (AZA) with Ruxolitinib

    First Tracks Biotherapeutics

    MDS/MPN

    phase 2 small molecule active

    1 trial

  13. Navitoclax, Navitoclax, RUXOLITINIB

    AbbVie Deutschland GmbH & Co. KG

    Myelofibrosis

    phase 2 small molecule active

    1 trial

  14. Rituximab Paclitaxel Ruxolitinib

    China SXT Pharmaceuticals

    Refractory Diffuse Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  15. RuxoTam; A phase II study to evaluate safety and efficacy of tamoxifen in combination with Ruxolitinib in patients with myelofibrosis

    Disc Medicine

    Myelofibrosis

    phase 2 other active

    1 trial

  16. Ruxolitinib

    First Tracks Biotherapeutics

    Bronchiolitis Obliterans Syndrome

    phase 2 small molecule active

    1 trial

  17. Ruxolitinib

    ACTUATE THERAPEUTICS, INC.

    Myelofibrosis

    phase 2 small molecule completed

    1 trial

  18. Ruxolitinib

    RIGEL PHARMACEUTICALS INC

    Coronavirus

    phase 2 small molecule completed

    1 trial

  19. Ruxolitinib

    China SXT Pharmaceuticals

    aGVHD

    phase 2 small molecule completed

    1 trial

  20. Ruxolitinib 5 MG BID Oral Tablet

    China SXT Pharmaceuticals

    The Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA

    phase 2 small molecule active

    1 trial

  21. A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, MULTIPLE RISING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF DEURUXOLITINIB IN HEALTHY ADULTS

    Pharma Mar S.A.

    alopecia areata

    phase 1 other active

    1 trial

  22. A Phase I study to evaluate the safety and efficacy of L19IL2 in combination with ruxolitinib in patients with advanced solid tumors.

    Philogen S.p.A.

    Advanced solid tumors, specifically: • metastatic clear cell renal carcinoma • proficient mismatch repair / microsatellite stable (pMMR/MSS), BRAF-V600E-mutant negative colorectal carcinoma • locally advanced or metastatic pancreatic adenocarcinoma

    phase 1 other active

    1 trial

  23. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Ruxolitinib Tablets, 20 mg, manufactured by Sun Pharmaceutical Industries Limited, India with JAKAVI (ruxolitinib) tablets 20 mg, (each Jakavi 20 mg tablet contains 26.40 mg of ruxolitinib phosphate equivalent to 20 mg of ruxolitinib). Imported by: Novartis Biociências SA Av. Prof. Vicente Rao, 90 - São Paulo - SP CNPJ: 56.994.502/0001-30. Manufactured by: Novartis Pharma Ste

    Pharma Mar S.A.

    Myelofibrosis, polycythemia vera, acute and chronic graft-versus-host-disease.

    phase 1 other active

    1 trial

  24. Bioequivalence of Ruxolitinib 20 mg Tablets in Healthy Participants Under Fasting Conditions.

    Pharma Mar S.A.

    No medical condition.

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources